Clinical Trial Update: A Phase 2b Study of Icosabutate in Fatty Liver Disease [Phase 2]

View source ↗

Summary

A Phase 2b trial of Icosabutate for nonalcoholic steatohepatitis (NASH) has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Icosabutate (icosabutate)

Snippet

Sponsor: NorthSea Therapeutics B.V. | Conditions: Non Alcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2025-02-28